The Histology and Cytology Market size was valued at USD 13,200.0 million in 2018 to USD 21,540.1 million in 2024 and is anticipated to reach USD 67,086.1 million by 2032, at a CAGR of 15.3% during the forecast period. The histology and cytology market occupies a central role in modern diagnostics and research, underpinning everything from routine cancer screening to advanced companion diagnostics and drug development. In 2024–2025 the sector has shown strong, sustained growth driven by rising cancer incidence, expanding screening programs in emerging markets, rapid technological innovation (automation, digital pathology, AI), and a steady shift toward minimally invasive testing and molecular integrations such as liquid biopsy. Together, these forces are transforming a historically fragmented, consumables-heavy market into a faster-moving, technology-led growth story.
Browse the full report at: https://www.credenceresearch.com/report/histology-and-cytology-market
Market size and growth
Estimates vary by researcher, but the consensus is clear: the market is large and growing at a doubledigit compound annual growth rate (CAGR). Recent market reports place the 2024–2025 global market in the roughly USD 18–22 billion range, with forecasts commonly projecting the market to at least double over the coming decade (CAGRs reported in the ≈10–15% range depending on horizon and segmentation). These projections reflect both growing test volumes worldwide and steadily rising per-test complexity and spend as laboratories adopt automation, digital slide scanning, and molecular adjuncts.
Key Growth Drivers
-
Rising oncology burden and screening: Increasing incidence of cancer worldwide and expanding screening programs (cervical, breast, colorectal, lung in selected populations) directly lifts demand for cytology and histology testing. Early detection initiatives and population screening strategies in emerging economies are notable growth levers.
-
Laboratory automation and digital pathology: To address pathologist shortages and scale growing case volumes, labs are buying automated tissue processors, stainers, slide scanners and digital image management solutions. Whole-slide imaging (WSI) and AI-based image analysis are moving from pilot projects into routine use, improving turnaround and enabling remote/centralized reads.
-
Integration with molecular diagnostics: Histology and cytology are no longer siloed from genomics — IHC, FISH and NGS from FFPE tissue or cytology specimens are routine for targeted therapies. The need for combined morphological and molecular information pushes labs to upgrade workflows and select vendors that provide integrated solutions.
-
Consumables-driven recurring revenue: Even as instrument sales rise, consumables and reagents continue to generate steady, recurring revenue — a major attraction for suppliers and a factor sustaining overall market value.
